Skip to main content
SpringerLink
Log in

Current Recommendations for the Management of Bladder Cancer

Drug Therapy

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Superficial transitional cell carcinoma of the bladder is a heterogeneous group of tumours, and prediction of disease outcome in an individual patient is still impossible. In low-risk patients the initial treatment [transurethral resection (TUR)] should be followed by no or only one immediate intravesical instillation with a chemotherapeutic drug to prevent a recurrence due to tumour cell implantation during TUR. Drug efficacy has been clearly demonstrated and adverse effects are very limited. Intermediate-risk patients should receive a course of additional intravesical instillations to reduce the recurrence rate with few adverse effects. All drugs seem to be equally effective, but the long term effects remain a question. In high-risk patients intravesical immunotherapy (BCG) should be given. Although toxicity is more pronounced, it is usually mild and adverse effects disappear after cessation of therapy. BCG (maintenance) therapy seems to be able to improve progression and ultimately tumour-related survival. It is important to know the advantages and disadvantages (adverse effects) of these treatment modalities to be able to individualise treatment as much as possible. The choice is difficult because several intravesical bladder cancer trials have not reached consensus on this.

For patients with non-metastasised invasive bladder tumours chemotherapy can be given before (neoadjuvant) or immediately after (adjuvant) surgery or radiotherapy. Both strategies have some advantages and disadvantages. For both, however, efficacy still needs to be proven, and results of ongoing trials are needed. For metastasised or recurrent urothelial cell carcinoma MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy remains the most effective treatment modality. Although initial response rates of between 40% and 70% can be achieved, most patients have a recurrence of their cancer. Moreover, toxicity of these drugs also is considerable and limiting. Leucopenia is responsible for the majority of grade III and IV toxicities and subsequent dose modifications. In case of toxic deaths, a leucopenic sepsis is usually the cause. Most other adverse effects are acceptable or can be treated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Incidence of cancer in the Netherlands: 1992. Netherlands Cancer Registry, Utrecht, 1992

  2. Kiemeney LALM, Straatman H, Witjes JA. Decreasing bladder cancer mortality in the Netherlands. Br J Urol 1996; 78: 686–90

    Article  PubMed  CAS  Google Scholar 

  3. Kiemeney LALM, Witjes JA, Verbeek ALM, et al. The clinical epidemiology of superficial bladder cancer. Observations among 1745 cases. Br J Cancer 1993; 67: 806–12

    Article  PubMed  CAS  Google Scholar 

  4. Lamm DL, Griffith JG. The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes). Prog Clin Biol Res 1992; 378: 43–53

    PubMed  CAS  Google Scholar 

  5. Soloway MS. Selecting initial therapy for bladder cancer. Cancer 1987; 60 Suppl.: 502–13

    Article  PubMed  CAS  Google Scholar 

  6. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 1991

    Google Scholar 

  7. Witjes JA, Kiemeney LALM, Oosterhof GON, et al. Prognostic factors in superficial bladder cancer. A review. Eur Urol 1992; 21: 89–97

    PubMed  CAS  Google Scholar 

  8. Morrison DA, Murphy WM, Ford KS, et al. Surveillance of stage 0, grade I bladder cancer by cytology alone: is it acceptable? J Urol; 1984; 132: 672–4

    PubMed  CAS  Google Scholar 

  9. Koontz Jr WW, Prout GR, Smith W, et al. The use of intravesical thiotepa in the management of non invasive carcinoma of the bladder. J Urol 1981; 125: 307–12

    PubMed  Google Scholar 

  10. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19: 529–39

    PubMed  CAS  Google Scholar 

  11. Richie JP. Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992; 19: 521–7

    PubMed  CAS  Google Scholar 

  12. Bouffioux C, Meijden A vd, Kurth KH, et al. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). Prog Clin Biol Res 1992; 378: 29–42

    PubMed  CAS  Google Scholar 

  13. MRC. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Br J Urol 1985; 57: 680–5

    Article  Google Scholar 

  14. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573–80

    PubMed  CAS  Google Scholar 

  15. Schulman C, Robinson M, Denis L, et al. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM 26) and TUR alone. Eur Urol 1982; 8: 207–12

    PubMed  CAS  Google Scholar 

  16. Novak R, Kern J, Fister H, et al. Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer. Eur Urol 1988; 14: 367–70

    PubMed  CAS  Google Scholar 

  17. Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 502–6

    PubMed  CAS  Google Scholar 

  18. Llopis B, Gallego J, Mompo JA, et al. Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors. Eur Urol 1985; 11: 73–8

    PubMed  CAS  Google Scholar 

  19. Crawford ED, McKenzie D, Mansson W, et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: a report of six cases. J Urol 1986; 136: 668–9

    PubMed  CAS  Google Scholar 

  20. Akaza H, Isaka S, Koiso K, et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 1987; 20: S91–95

    Article  PubMed  Google Scholar 

  21. Matsumura Y, Akaze H, Isaka S, et al. The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group for adriamycin. Cancer Chemother Pharmacol 1992; 30: S10–14

    Article  PubMed  Google Scholar 

  22. Debruyne FMJ, vd Meijden APM, Witjes JA, et al. Bacillus Calmette-Guerin versus mitomycin-C intravesical therapy in superficial bladder cancer. Results of a randomized trial after 21 months of follow up. Urology 1992, 40 Suppl.: 11–5

    Article  Google Scholar 

  23. Witjes JA, vd Meijden APM, Witjes WPJ, et al. A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Intravesical instillations in superficial bladder cancer. Eur J Cancer 1993; 29A: 1672–6

    Article  PubMed  CAS  Google Scholar 

  24. deGroot AC, Meijden APM vd, Conemans JMH et al. Frequency and nature of cutaneous reactions to intravesical instillation of mitomycin for superficial bladder cancer. Urology 1992; 40 Suppl.: 16–9

    Article  Google Scholar 

  25. Meijden APM vd, Kurth KH, Oosterlink W, et al. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU group. Cancer Chemother Pharmacol 1992; 30: S95–98

    Article  PubMed  Google Scholar 

  26. Burk K, Kurth KH, Newling D. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog Clin Biol Res 1989; 303: 423–34

    PubMed  CAS  Google Scholar 

  27. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organisation for Research and Treatment of Cancer Genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149: 749–52

    PubMed  CAS  Google Scholar 

  28. Walker L, Walker MC, Parris CN, et al. Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity n vitro. Urol Res 1988; 16: 329–31

    Article  PubMed  CAS  Google Scholar 

  29. Ohtani M, Miyanage N, Imada S, et al. Promotive effect of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice. Abstract. J Urol 1994; 151: 391A

    Google Scholar 

  30. Long JP, Prout Jr GR, Yau Kai Wong, et al. The effect of verapamil on multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J Urol 1990; 143: 1053–6

    PubMed  Google Scholar 

  31. Ohi Y, Ohmori H, Shirahama T, et al. Intravesical instillation of adriamycin an the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother Pharmacol 1992; 30: S50–54

    Article  PubMed  Google Scholar 

  32. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180–3

    PubMed  CAS  Google Scholar 

  33. Glashan RW. A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658–61

    PubMed  CAS  Google Scholar 

  34. Chodak GW. Intravesical interferon treatment of superficial bladder cancer. Urology 1989; 34: 84–96

    Article  PubMed  CAS  Google Scholar 

  35. Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al. Profilaxis del cancer vesical superficial con 1 mg de BCG endovesical: comparacion con otras dosis. Actas Urol Esp 1993; 17: 239–42

    PubMed  CAS  Google Scholar 

  36. Martinez-Pineiro JA, Solsona E, Flores N, et al: Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 Suppl. 1: 13–8

    PubMed  Google Scholar 

  37. Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 Suppl. 1: 19–22

    PubMed  Google Scholar 

  38. Mack D, Frick J. Five year results of a phase II study with low-dose BCG therapy in high risk superficial bladder cancer. Urology 1995; 45: 958–61

    Article  PubMed  CAS  Google Scholar 

  39. Witjes JA, Fransen MPH, vd Meijden APM, et al. Use of maintenance intravesical bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long term follow up of a randomised phase 2 study. Urol Int 1993; 51: 67–72

    Article  PubMed  CAS  Google Scholar 

  40. Witjes JA, vd Meijden APM, Debruyne FMJ. Use of intravesical Bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int 1990; 45: 129–36

    Article  PubMed  CAS  Google Scholar 

  41. Lamm DL, Stogdill VD, Stogdill BJ, et al. Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272–4

    PubMed  CAS  Google Scholar 

  42. Lamm DL, Crissman J, Blumenstein B, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis L, vd Meijden APM, editors. EORTC Genito-Urinary Group Monograph 6: BCG in Superficial bladder cancer. New York: Alan R. Liss Inc., 1989: 335–55

    Google Scholar 

  43. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205–9

    Article  PubMed  CAS  Google Scholar 

  44. Simmons WB, Reichert DF, Lucio RM, et al. Pyrimidinone Interferon Inducers in the Treatment of Murine Transitional Cell Carcinoma. J Urol 1983; 129: 169

    Google Scholar 

  45. Sarosdy MF, Lamm DL, Williams RD, et al. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 31–3

    PubMed  CAS  Google Scholar 

  46. Sarosdy MF, Lowe BA, Schellhammer PF, et al. Bropirimine immunotherapy of bladder CIS: positive phase II results of an oral interferon. Abstract. J Urol 1994; 151: 304A

    Google Scholar 

  47. Pawinski A, Bouffioux C, Sylvester R, et al. Meta-analysis of EORTC/MRC randomised clinical trials for the prophylactic treatment of Ta,Tl bladder cancer. J Urol 1996; 155: 492A

    Google Scholar 

  48. Akaza H, Kioso K, Kotake T, et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992; 30: S15–20

    Article  PubMed  Google Scholar 

  49. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow up. J Urol 1992; 147: 1020–3

    PubMed  CAS  Google Scholar 

  50. Harker WG, Meyers FJ, Frieha FS, et al. Cisplatin, metotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol 1985; 3: 1463–70

    PubMed  CAS  Google Scholar 

  51. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (metotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461–9

    PubMed  CAS  Google Scholar 

  52. Stoter G, Splinter TAW, Child JA, et al. Combination chemotherapy with cisplatin and metotrexate in advanced transitional cell cancer of the bladder. J Urol 1987; 137: 663–7

    PubMed  CAS  Google Scholar 

  53. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (metotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988; 139: 470–4

    PubMed  CAS  Google Scholar 

  54. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. J Urol 1996; 155: 1903–6

    Article  PubMed  CAS  Google Scholar 

  55. Hall RR. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial. Abstract. Proceedings ASCO 1996. J Clin Oncol 1996; 15: 244

    Google Scholar 

  56. Logothetis C, Swanson D, Amato R, et al. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and post-operative chemotherapy for invasive bladder carcinoma. J Urol 1996; 155: 1241–5

    Article  PubMed  CAS  Google Scholar 

  57. Skinner DG, Daniels JR, Russel CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459–67

    PubMed  CAS  Google Scholar 

  58. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 504–5

    Article  Google Scholar 

  59. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403–7

    PubMed  CAS  Google Scholar 

  60. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response. Cancer 1989; 64: 2448–58

    Article  PubMed  CAS  Google Scholar 

  61. Logothetis CJ, Dexeus FH, Finn FH, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050–5

    PubMed  CAS  Google Scholar 

  62. Loerher PJ, Einhorn LH, Elson PH, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. A Cooperative group study. J Clin Oncol 1992; 10: 1066–73

    Google Scholar 

  63. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent of metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 244–51

    Article  Google Scholar 

  64. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150: 1131–4

    PubMed  CAS  Google Scholar 

  65. Logothetis C, Dieringer P, Ellerehorst J, et al. A 61% response rate with 5-fluorouracil, interferon-alpha2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc AACR 1992; 33: 221

    Google Scholar 

  66. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the princess Margaret hospital experience. J Urol 1989; 142: 289–92

    PubMed  CAS  Google Scholar 

  67. Witjes JA, Wullink M, Oosterhof GON, et al. Toxicity and results of MVAC chemotherapy in advanced transitional cell carcinoma. Eur Urol. In press

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospital, Nijmegen, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    J. Alfred Witjes

Authors
  1. J. Alfred Witjes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Witjes, J.A. Current Recommendations for the Management of Bladder Cancer. Drugs 53, 404–414 (1997). https://doi.org/10.2165/00003495-199753030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199753030-00005

Keywords

Search

Navigation